Fibroblast growth factor receptor

Incyte Announces Data from Across its Oncology Portfolio will be Presented at the AACR Annual Meeting 2023

Retrieved on: 
Tuesday, March 14, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Molecule, Phosphatidylinositol, AACR, Lenalidomide, Lung cancer, APC Activator, Abstract, DLBCL, Clinical trial, Refractory, Anemia, Relapse, Potent, Tumor microenvironment, Phosphatase, BTK, BET inhibitor, Drug resistance, Bone marrow, MPN, Myeloproliferative neoplasm, ALK2, American Association for Cancer Research, Efficacy, Treatment, Fibroblast growth factor receptor, FGFR, Pharmaceutical industry, Vaccine, Patient, Macrophage, Incyte, Primary myelofibrosis, Pemigatinib

Incyte (Nasdaq:INCY) today announced that multiple abstracts from across its oncology portfolio will be presented during the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023, held April 14-19, in Orlando, Florida.

Key Points: 
  • Incyte (Nasdaq:INCY) today announced that multiple abstracts from across its oncology portfolio will be presented during the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023, held April 14-19, in Orlando, Florida.
  • ET)
    Five-Year Safety and Efficacy of Tafasitamab in Patients with Relapsed or Refractory DLBCL: Final Results from the Phase 2 L-MIND Study1(Abstract #CT022.
  • ET)
    For registered attendees, the virtual meeting platform and all on-demand sessions will be available through July 19, 2023.
  • More information regarding the AACR Annual Meeting 2023 can be found at https://www.aacr.org/meeting/aacr-annual-meeting-2023/ .

Tyra Biosciences to Present at Upcoming Investor Conferences

Retrieved on: 
Thursday, November 10, 2022
Investor, Fibroblast growth factor receptor 1, Nasdaq, Cancer, SNP, Webcast, Fibroblast growth factor receptor, Chromosomal rearrangement, CA, FGFR4, Transfection, Company, Science, Conference, FGFR, Patient, CEO, FGFR3, Achondroplasia, FGFR2, RET, Pharmaceutical industry, Security (finance), Cholangiocarcinoma

Webcasts of the fireside chats will be available via the For Investors page on the Investor section of the TYRA website.

Key Points: 
  • Webcasts of the fireside chats will be available via the For Investors page on the Investor section of the TYRA website.
  • Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer.
  • TYRA-200 is an FGFR1/2/3 inhibitor with potency against FGFR2 fusions, molecular brake mutations and gatekeeper resistance that TYRA is developing initially in intrahepatic cholangiocarcinoma.
  • TYRA is also targeting achondroplasia and other FGFR3-related skeletal dysplasias and FGFR4 and RET (REarranged during Transfection kinase) driven cancers.

Tyra Biosciences Announces Planned Chief Financial Officer Transition

Retrieved on: 
Wednesday, November 2, 2022
Security (finance), Agricultural economics, Growth, Montana State University, FGFR3, Risk, CEO, Vinylcyclopropane rearrangement, Fibroblast growth factor receptor, MicroRNA, Acquisition, U.S. Securities and Exchange Commission, Annual report, Daiichi Sankyo, FGFR, SEC, Cancer, Esperies, Research, AbbVie, FGFR4, Regeneron Pharmaceuticals, Business administration, Esperion Therapeutics, IND, Nasdaq, COVID-19, FGFR2, Agriculture, Fibroblast growth factor receptor 1, Eli Lilly, SNP, CFO, Form 10-K, RET, Sale, PricewaterhouseCoopers, Private Securities Litigation Reform Act, Achondroplasia, Transfection, Therapy, FDA, Patient, Audit committee, Cooper, Science, CA, Pharmaceutical industry, Cholangiocarcinoma

CARLSBAD, Calif., Nov. 2, 2022 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today announced that its Chief Financial Officer, Esther van den Boom, will be stepping down to transition into an advisory role at the end of 2022. TYRA also announced that Alan Fuhrman has been appointed as Chief Financial Officer effective January 1, 2023, and Ms. van den Boom will support the transition. 

Key Points: 
  • CARLSBAD, Calif., Nov. 2, 2022 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today announced that its Chief Financial Officer, Esther van den Boom, will be stepping down to transition into an advisory role at the end of 2022.
  • TYRA also announced that Alan Fuhrman has been appointed as Chief Financial Officer effective January 1, 2023, and Ms. van den Boom will support the transition.
  • Prior to that, Mr. Fuhrman served as the Chief Financial Officer of Amplyx Pharmaceuticals, Inc. from December 2017 through June 2020.
  • "It has been my privilege to serve as Chief Financial Officer of TYRA since shortly after the company's inception," said Ms. van den Boom.

Tyra Biosciences to Participate at September 2022 Investor Conferences

Retrieved on: 
Thursday, September 8, 2022
CA, Achondroplasia, Cancer, Fibroblast growth factor receptor 1, SNP, FGFR, Fibroblast growth factor receptor, RET, LinkedIn, Science, FGFR4, Chromosomal rearrangement, Nasdaq, Transfection, FGFR2, FGFR3, Patient, Medical imaging, Pharmaceutical industry, Cholangiocarcinoma

CARLSBAD, Calif., Sept. 8, 2022 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today announced that management will participate at the following investor conferences:

Key Points: 
  • CARLSBAD, Calif., Sept. 8, 2022 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today announced that management will participate at the following investor conferences:
    Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer.
  • Leveraging SNP, TYRA is developing a pipeline of selective inhibitors of Fibroblast Growth Factor Receptors (FGFR), which are altered in approximately 7% of all cancers.
  • TYRA-200 is an FGFR2 inhibitor that TYRA is developing initially in intrahepatic cholangiocarcinoma.
  • TYRA is also targeting achondroplasia and other FGFR3-related skeletal dysplasias and FGFR4 and REarranged during Transfection kinase (RET) related cancers.

Tyra Biosciences to Present Preclinical Data on TYRA-300, an FGFR3-selective Inhibitor, at ESMO 2022 Congress

Retrieved on: 
Monday, September 5, 2022
European Society for Medical Oncology, Investigational New Drug, COVID-19, CA, Security (finance), CEO, Achondroplasia, Cancer, MTD, Research, Form 10-K, IND, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Fibroblast growth factor receptor 2, SNP, FGFR, Fibroblast growth factor receptor, Risk, FGFR3, RET, Hyperphosphatemia, FGFR1, Food, ESMO, LinkedIn, Science, SEC, Time-invariant system, Vinylcyclopropane rearrangement, U.S. Securities and Exchange Commission, Nasdaq, Company, FDA, Oncology, Transfection, FGFR2, Congress, Annual report, Private Securities Litigation Reform Act, Trial of the century, Patient, Pharmaceutical industry, Cholangiocarcinoma

"We believe the preclinical results being presented at the ESMO Congress showcase the enhanced anti-tumor activity and selectivity of TYRA-300 as compared to other agents in the class," said Todd Harris, CEO of TYRA.

Key Points: 
  • "We believe the preclinical results being presented at the ESMO Congress showcase the enhanced anti-tumor activity and selectivity of TYRA-300 as compared to other agents in the class," said Todd Harris, CEO of TYRA.
  • Details of the poster presentation are as follows:
    Regular abstracts will be published on the ESMO website on September 5, 2022.
  • The poster presentation on TYRA-300 will be made available on the TYRA website under the "For Investors" section on September 12, 2022.
  • TYRA cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements.

J INTS BIO, Oral presentation of Preclinical results of its Novel Oral 4th Generation EGFR TKI 'JIN-A02' at the 2022 World Conference on Lung Cancer in Vienna, Austria (IASLC 2022 WCLC)

Retrieved on: 
Tuesday, August 16, 2022
General of the branch, Lung cancer, Permeability, Patient safety, Drug discovery, Recurrence, Brain, Cancer, Patient, EGFR, TKI, Fibroblast growth factor receptor, Cros, Conference, Traffic barrier, Health, Pharmaceutical industry, Osimertinib, NSCLC

Prof. Cho Byoung-chul, Director of the Lung Cancer Center at Yonsei Cancer Hospital, Korea, presented data which indicates that 'JIN-A02' targets NSCLC cancers harboring double or triple C797S mutations.

Key Points: 
  • Prof. Cho Byoung-chul, Director of the Lung Cancer Center at Yonsei Cancer Hospital, Korea, presented data which indicates that 'JIN-A02' targets NSCLC cancers harboring double or triple C797S mutations.
  • Prof. Cho ended his presentation by putting forth that JIN-A02 may be the Best-In-Class 4th generation EGFR-TKI against NSCLC.
  • 'JIN-A02' is a novel orally administered 4th Generation EGFR TKI targeting C797S mutations in NSCLC.
  • Although 1st, 2nd, and 3rd Generation EGFR TKIs have been used with some success, recurrence occurs in most patients including 3rd Generation TKIs such as Osimertinib.

J INTS BIO, Oral presentation of Preclinical results of its Novel Oral 4th Generation EGFR TKI 'JIN-A02' at the 2022 World Conference on Lung Cancer in Vienna, Austria (IASLC 2022 WCLC)

Retrieved on: 
Tuesday, August 16, 2022
General of the branch, Lung cancer, Multimedia, Permeability, Patient safety, Drug discovery, Recurrence, Brain, Cancer, Patient, EGFR, TKI, Fibroblast growth factor receptor, Cros, Conference, Traffic barrier, Health, Pharmaceutical industry, Vaccine, Osimertinib, NSCLC

Prof. Cho Byoung-chul, Director of the Lung Cancer Center at Yonsei Cancer Hospital, Korea, presented data which indicates that 'JIN-A02' targets NSCLC cancers harboring double or triple C797S mutations.

Key Points: 
  • Prof. Cho Byoung-chul, Director of the Lung Cancer Center at Yonsei Cancer Hospital, Korea, presented data which indicates that 'JIN-A02' targets NSCLC cancers harboring double or triple C797S mutations.
  • Prof. Cho ended his presentation by putting forth that JIN-A02 may be the Best-In-Class 4th generation EGFR-TKI against NSCLC.
  • 'JIN-A02' is a novel orally administered 4th Generation EGFR TKI targeting C797S mutations in NSCLC.
  • Although 1st, 2nd, and 3rd Generation EGFR TKIs have been used with some success, recurrence occurs in most patients including 3rd Generation TKIs such as Osimertinib.

Allarity Therapeutics Refocuses Oncology Pipeline Strategy Towards Combination Therapies

Retrieved on: 
Tuesday, August 2, 2022
Regulation of tobacco by the U.S. Food and Drug Administration, Cisplatin, Time, Doxorubicin, Literature, MRCC, GBM, Type, U.S. Securities and Exchange Commission, Food, Ixabepilone, Trial of the century, Forward-looking statement, Fibroblast growth factor receptor, Partnership, Private Securities Litigation Reform Act, NDA, Risk, Board, Therapy, COVID-19, Coronavirus Scientific Advisory Board (Turkey), Cancer, Clinical trial, FDA, Company, Board of directors, Patient, Interim, Nasdaq, PARP, Security (finance), Â, Glioblastoma, Ovarian cancer, SAB, RNA, Pharmaceutical industry, Allare Allari

Cambridge, MA, U.S.A. (August 2, 2022) Allarity Therapeutics, Inc. (Allarity or the Company), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP companion diagnostics for personalized cancer care, today announced that its Board of Directors has mandated a refocus of the Companys oncology pipeline strategy away from development of monotherapies towards development of more promising and clinically relevant combination therapies.

Key Points: 
  • Cambridge, MA, U.S.A. (August 2, 2022) Allarity Therapeutics, Inc. (Allarity or the Company), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP companion diagnostics for personalized cancer care, today announced that its Board of Directors has mandated a refocus of the Companys oncology pipeline strategy away from development of monotherapies towards development of more promising and clinically relevant combination therapies.
  • Significantly broaden the Companys possibilities for future commercial partnering with larger pharmaceutical companies to maximize the value of its pipeline assets and DRP platform technology.
  • The Company is currently evaluating other potential Phase 1b/2 studies for either stenoparib or dovitinib combined with another oncology therapeutic, including the mRCC space.
  • Allarity Therapeutics, Inc. (Nasdaq: ALLR) develops drugs for personalized treatment of cancer guided by its proprietary and highly validated companion diagnostic technology, the DRP platform.

Kinnate Biopharma Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of its FGFR Inhibitor Product Candidate, KIN-3248

Retrieved on: 
Monday, April 18, 2022
Sarah Cannon Research Institute, Clinical trial, Squamous cell carcinoma, Pharmacokinetics, Part, KNTE, Fibroblast growth factor receptor, ICC, U.S. Securities and Exchange Commission, COVID-19, Adult, Risk, Security (finance), Annual report, MD, GLOBE, Doctor of Philosophy, Patient, SAN, Growth, Nasdaq, FGFR2, FGFR3, UC, SEC, Safety, Assistant, Industry, MBBS, Cancer, Cholangiocarcinoma, Therapy, Pharmaceutical industry, FGFR

KIN-3248 is a next-generation pan-FGFR inhibitor being developed for the treatment of intrahepatic cholangiocarcinoma (ICC) and urothelial carcinoma (UC), as well as other solid tumors.

Key Points: 
  • KIN-3248 is a next-generation pan-FGFR inhibitor being developed for the treatment of intrahepatic cholangiocarcinoma (ICC) and urothelial carcinoma (UC), as well as other solid tumors.
  • We are grateful for the contribution of all the participants in this multi-center trial and for the support of our clinical collaborators at each trial site.
  • In preclinical studies, KIN-3248 demonstrated inhibitory activity across a wide range of clinically relevant mutations that drive primary disease and acquired resistance to other FGFR inhibitors.
  • We are proud to be the first site to treat a patient with KIN-3248 and look forward to working with Kinnate to continue enrollment in this important Phase 1 trial.

Kinnate Biopharma Inc. to Present Preclinical Data on its FGFR Inhibitor Candidate at the ASCO Gastrointestinal Cancers Symposium

Retrieved on: 
Wednesday, January 19, 2022
IC50, Patient, KNTE, MBBS, Gastrointestinal cancer, SAN, FGFR, Clinical trial, Cholangiocarcinoma, SEC, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, COVID-19, FGFR2, Growth, EC50, HIV disease progression rates, Poster, GLOBE, Â, Cancer, FGFR1, Translational medicine, U.S. Securities and Exchange Commission, Nasdaq, Industry, Program, FGFR3, Therapy, Food, Immortalised cell line, ASCO, Investigational New Drug, FGFR4, Security (finance), Fibroblast growth factor receptor, Risk, ICC, Pharmaceutical industry

These findings will be presented during a poster session at the ASCO Gastrointestinal Cancers Symposium taking place in San Francisco, January 20-22, 2022.

Key Points: 
  • These findings will be presented during a poster session at the ASCO Gastrointestinal Cancers Symposium taking place in San Francisco, January 20-22, 2022.
  • Oncogenic FGFR (FGFR1, FGFR2, FGFR3, and FGFR4) gene alterations are observed in approximately 7% of all human cancers.
  • KIN-3248 has been evaluated across wild-type FGFR family members and clinically relevant fusions and kinase domain resistance mutations in vitro.
  • Additional information on the ASCO GI Cancers Symposium is available through the conference website at: https://conferences.asco.org/gi .